UPB - Upstream Bio Inc Dividends
This article provides detailed financial data and performance metrics for Upstream Bio Inc. (UPB). It lists various financial ratios, stock performance over different periods, insider and institutional ownership, and analyst recommendations, noting that the company does not currently pay dividends. The report covers essential investment-related information without offering a narrative.
Price to sales forward of Upstream Bio, Inc. – NASDAQ:UPB
The article focuses on the "Price to sales forward" metric for Upstream Bio, Inc. (NASDAQ: UPB). It provides a snapshot of the company's financial data on TradingView, indicating that the market was closed at the time of viewing. The content is primarily a data point with no further detailed analysis or commentary.
If You Invested $1,000 in UpStream Bio Inc. (UPB)
This article examines the historical performance of a $1,000 investment in UpStream Bio Inc. (UPB), a clinical-stage biotechnology company focused on inflammatory diseases. It provides detailed information on UPB's core drug candidate, verekitug, its mechanism of action, and its progress through Phase 2 clinical trials for conditions like CRSwNP, severe asthma, and COPD. The content includes financial data, year-by-year returns, and comparative analysis with the S&P 500.
Here's Why We're Watching Upstream Bio's (NASDAQ:UPB) Cash Burn Situation
This article examines Upstream Bio's cash burn rate and its implications for the company's future operations. It analyzes the current cash reserves against the burn rate to estimate how long the company can continue funding its activities without additional capital. The article highlights the importance of managing cash burn for biotechnology companies in the clinical development phase.
Enterprise value to EBIT forward of Upstream Bio, Inc. – NASDAQ:UPB
The article focuses on the enterprise value to EBIT forward ratio for Upstream Bio, Inc., trading under the NASDAQ symbol UPB. It appears to be a financial data point presented within a trading platform context, with placeholders for actual financial figures.
Upstream Bio, Inc. Actuals & Estimates (NASDAQ:UPB)
This article provides an overview of Upstream Bio, Inc. (NASDAQ: UPB) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details key financial actuals and estimates such as earnings per share and revenue, indicating the company's next earnings report is due on August 12, 2026.
Upstream Bio, Inc. (UPB) reports Q1 loss, beats revenue estimates
Upstream Bio, Inc. (UPB) reported a Q1 loss per share of $0.93, which was lower than the analyst estimate of a $1.09 loss per share. The company also announced Q1 revenue of $180,000, surpassing the analyst consensus estimate of $170,000.
Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?
Upstream Bio, Inc. (NASDAQ:UPB) is highlighted as a promising small-cap stock following new analyst coverage from H.C. Wainwright, which initiated a Buy rating and a $36 price target. The analyst praised the company's lead candidate, verekitug, an antibody targeting the thymic stromal lymphopoietin receptor, for its potential efficacy and differentiated quarterly subcutaneous dosing. Additionally, Upstream Bio recently presented positive Phase 2 VIBRANT trial results for verekitug in chronic rhinosinusitis with nasal polyps, showing clinically meaningful reductions in nasal polyp scores.
Upstream Bio Inc (UPB) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Upstream Bio Inc (UPB), covering its current price momentum, support and resistance levels, and various technical indicators and moving averages. According to the analysis, UPB's price momentum score is 6.46, and it's trading between a resistance level of 7.94 and a support level of 5.10, suggesting suitability for range-bound swing trading. While some indicators show "buy" signals, moving averages predominantly signal "sell."
Upstream Bio Inc (UPB) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Upstream Bio Inc's (UPB) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and shows no data for past stock splits. The page includes current stock price information, market capitalization, and P/E TTM.
Upstream Bio Inc (UPB) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Upstream Bio Inc (UPB), noting its current valuation score is 8.14, ranking 168 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -2.04 and states that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed. The stock closed at $6.03 with a market cap of $328.15M.
Upstream Bio Reports Positive Phase 2 Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps, Achieving Clinically Meaningful Improvements in Key Symptoms
Upstream Bio announced positive Phase 2 results for its drug verekitug in treating chronic rhinosinusitis with nasal polyps (CRSwNP). The trial demonstrated significant improvements in nasal polyp scores and key secondary endpoints like nasal congestion and total symptom scores, with 80% of participants showing meaningful improvement. Upstream Bio plans to initiate Phase 3 trials in both CRSwNP and severe asthma in early 2027, highlighting verekitug's potential as a promising, quarterly-dosed treatment option for these conditions.
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
Upstream Bio presented new responder analyses from its Phase 2 VIBRANT trial for verekitug, showing clinically meaningful improvements in chronic rhinosinusitis with nasal polyps (CRSwNP). The data indicated that approximately 80% of participants treated with verekitug every three months experienced significant improvements across primary and key secondary endpoints, including nasal polyp score, congestion, and total symptom score. The company plans to advance to Phase 3 trials for CRSwNP and severe asthma in Q1 2027, highlighting verekitug's potential as a differentiated and convenient biologic treatment.
Quarterly nasal polyp treatment improved symptoms for most trial patients
Upstream Bio presented new analyses from its Phase 2 VIBRANT trial for verekitug, showing clinically meaningful improvements in chronic rhinosinusitis with nasal polyps (CRSwNP) symptoms for a significant majority of patients with quarterly dosing. Approximately 80% achieved improvement in nasal polyp score, with 72% for nasal congestion and 83% for total symptom score, nearly doubling the clinically meaningful threshold. The company plans to start Phase 3 trials for CRSwNP and severe asthma in Q1 2027.
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
Upstream Bio presented new responder analyses from its Phase 2 VIBRANT trial for verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) at the EAACI 2026 Congress. The data showed that approximately 80% of participants treated with verekitug achieved clinically meaningful improvements in nasal polyp score and other key secondary endpoints like nasal congestion, sense of smell, and total symptom score. The company plans to initiate Phase 3 trials for CRSwNP and severe asthma in the first quarter of 2027, highlighting verekitug's potential as a differentiated and durable biologic therapy.
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
Upstream Bio presented new responder analyses from its Phase 2 VIBRANT trial for verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP), demonstrating clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants. The study also showed significant improvements in nasal congestion and total symptom score. These findings support verekitug's potential as a differentiated and durable treatment, with Phase 3 trials planned for CRSwNP and severe asthma in early 2027.
Upstream Bio Cut to Neutral From Overweight by JP Morgan
JP Morgan has downgraded Upstream Bio's rating from Overweight to Neutral. This change in rating suggests a revised outlook on the company's stock performance by the investment bank.
JPMorgan Downgrades Upstream Bio to Neutral From Overweight, Cuts Price Target to $8 From $35
JPMorgan downgraded Upstream Bio (UPB) from Overweight to Neutral and significantly cut its price target from $35 to $8. This adjustment reflects a revised outlook from the investment bank regarding the biotechnology company. Upstream Bio is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders.
J.P. Morgan Downgrades UpStream Bio(UPB.US) to Hold Rating, Announces Target Price $8
J.P. Morgan has downgraded UpStream Bio (UPB.US) from an Overweight to a Hold rating. The firm also announced a new target price of $8 for the company's stock. This change in rating reflects J.P. Morgan's updated outlook on UpStream Bio's financial performance and market potential.
Upstream Bio Shareholders Elect Directors, Ratify 2026 Auditor
Upstream Bio, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected two Class II directors, H. Edward Fleming, Jr., M.D., and Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A., to serve until the 2029 annual meeting. Investors also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Despite a "Neutral" rating from TipRanks' AI Analyst, citing heavy losses and accelerating cash burn, the company maintains a strong, low-debt balance sheet.
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
Upstream Bio announced that additional efficacy data from its Phase 2 VIBRANT trial of verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented in an oral session at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 Congress. The presentation will feature a responder analysis showing clinically meaningful improvements in key disease measures. Verekitug is a TSLP receptor antagonist, targeting a key driver of inflammatory responses in allergic and inflammatory diseases.
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
Upstream Bio will present additional efficacy data from its Phase 2 VIBRANT trial of verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) at the EAACI 2026 Congress. The presentation will include a responder analysis showing clinically meaningful improvements for patients treated with verekitug, which is a novel TSLP receptor antagonist. Verekitug is also being investigated in Phase 2 trials for severe asthma and COPD.
Upstream Bio To Showcase Additional Efficacy Data From The Phase 2 Vibrant Trial Of Verekitug In Crswnp In Oral Session At Eaaci 2026
Upstream Bio is set to present further efficacy data from its Phase 2 Vibrant trial of Verekitug. This presentation, focusing on CRSwNP, will take place during an oral session at EAACI 2026. The news was released by Refinitiv and is a brief announcement regarding the upcoming data showcase.
Nasal polyp drug Verekitug Phase 2 data to be aired at EAACI 2026
Upstream Bio (NASDAQ: UPB) will present additional efficacy data from its Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP) at the EAACI 2026 Congress on June 14, 2026. The presentation will feature a responder analysis highlighting clinically meaningful improvements in key disease measures. Verekitug is noted as the only known TSLP receptor antagonist currently in clinical development for inflammatory diseases.
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
Upstream Bio will present additional efficacy data from its Phase 2 VIBRANT trial of verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) at the EAACI 2026 Congress. The presentation will include a responder analysis highlighting clinically meaningful improvements. Verekitug is a novel TSLP receptor antagonist antibody currently in advanced clinical development for multiple inflammatory diseases.
Upstream Bio (UPB) price target decreased by 18.03% to 51.00
Upstream Bio's price target has been decreased by 18.03% to $51.00. This adjustment indicates a notable change in the financial outlook for the company.
Upstream Bio (UPB) price target decreased by 18.03% to 51.00
The price target for Upstream Bio (UPB) has been reduced by 18.03% to $51.00. This adjustment indicates a revised outlook on the company's valuation. Further details regarding the reasons for this change were not provided in the snippet.
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Upstream Bio, a clinical-stage biotechnology company, announced that its CEO, Rand Sutherland, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company is developing verekitug, an antagonist targeting the TSLP receptor, for inflammatory diseases like chronic rhinosinusitis with nasal polyps, severe asthma, and COPD. A live webcast and replay of the presentation will be available on Upstream Bio's investor relations website.
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Upstream Bio, a clinical-stage biotechnology company, announced that its CEO, Rand Sutherland, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 10:40 a.m. ET. The company is developing verekitug, a monoclonal antibody targeting TSLP, for severe respiratory disorders including chronic rhinosinusitis with nasal polyps, severe asthma, and chronic obstructive pulmonary disease. A live webcast and replay of the presentation will be available on the Investors section of their website.
UPB Initiates Coverage On HC Wainwright & Co. -- Rating Set to Buy
HC Wainwright & Co. has initiated coverage on Upstream Bio (UPB) with a "Buy" rating and a price target of $36.00. While this indicates a positive outlook for the biotechnology company, particularly concerning its treatments for respiratory disorders, Upstream Bio's GF Score™ of 12/100 points to significant weaknesses in profitability and growth. Investors are cautioned to consider these financial metrics and the lack of insider purchases despite the positive analyst rating.
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Upstream Bio, a clinical-stage biotechnology company, announced that its CEO, Rand Sutherland, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The presentation will be webcast live and a replay will be available on the company's website. Upstream Bio focuses on developing treatments for inflammatory diseases, specifically targeting severe respiratory disorders with their drug, verekitug.
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Upstream Bio, Inc. announced that its CEO, Rand Sutherland, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 10:40 a.m. ET. A live webcast and replay will be available on the company's investor website. Upstream Bio is a clinical-stage biotechnology company focused on inflammatory diseases and is developing verekitug, a monoclonal antibody for conditions like chronic rhinosinusitis with nasal polyps, severe asthma, and chronic obstructive pulmonary disease.
UPB Technical Analysis | Trend, Signals & Chart Patterns | UPSTREAM BIO INC (NASDAQ:UPB)
This report provides a technical analysis of UPSTREAM BIO INC (UPB), noting its poor technical rating of 0 out of 10 due to negative short and long-term trends and underperformance compared to the broader market and many industry peers. Despite a negative outlook, the stock exhibits a decent setup pattern with consolidating prices and reduced volatility, alongside identified support and resistance levels. Key indicators, including SMAs and ADX, confirm a negative trend, while a bear flag pattern suggests potential short opportunities.
UPB News | UPSTREAM BIO INC (NASDAQ:UPB)
This article provides news and analysis for Upstream Bio Inc. (NASDAQ: UPB), including its current stock price and recent press releases. Key updates include data presented from a Phase 2 trial of Verekitug and the company's Q1 2026 financial results which beat revenue estimates.
Number of shareholders of Upstream Bio, Inc. – NASDAQ:UPB
This article provides the title and stock ticker for Upstream Bio, Inc. (NASDAQ: UPB) and indicates it is about the number of shareholders. It appears to be a stub or a placeholder page from a financial data platform, as no actual shareholder data is presented, only navigation and copyright information.
Upstream Bio Maintained at Buy as Verekitug’s Differentiated Efficacy Supports Steady $42 Price Target
LifeSci Capital analyst Kate Dellorusso reiterated a Buy rating on Upstream Bio (UPST) with a steady $42 price target. This rating is based on the compelling efficacy data of verekitug for asthma and chronic rhinosinusitis with nasal polyps, showing reduced need for steroids/surgery and improved disease endpoints. The drug's broad impact on Type 2 inflammation biomarkers and its potential as a first-in-class TSLP inhibitor support its competitive positioning and the continued Buy recommendation.
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
Upstream Bio presented new data from its Phase 2 VIBRANT trial of verekitug, showing significant improvement in asthma symptom control for participants with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma. The drug also reduced nasal polyp scores and type 2 inflammatory biomarkers. These findings support verekitug's potential as a best-in-class treatment, with Phase 3 trials in CRSwNP and severe asthma planned for Q1 2027.
Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data for verekitug in CRSwNP at ATS2026
Upstream Bio, Inc. presented new Phase 2 VIBRANT trial data for verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) at ATS2026. The findings included data on patients with comorbid asthma, offering important insights into the therapeutic response for this patient population. This release highlights the ongoing development of the investigational antibody therapy to address an area of significant unmet medical need.
Upstream Bio Announces Positive Phase 2 VIBRANT Trial Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma
Upstream Bio announced positive Phase 2 VIBRANT trial results for verekitug, demonstrating significant improvements in asthma control and nasal polyp scores in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma. The treatment reduced the need for systemic corticosteroids or surgery by 83% in these patients and showed rapid, sustained reductions in inflammatory biomarkers. Upstream Bio plans to initiate Phase 3 trials for verekitug in CRSwNP and severe asthma in early 2027.
New sinus and asthma drug trial slashes steroid use, sinus surgery by 83%
Upstream Bio (NASDAQ: UPB) announced new Phase 2 VIBRANT trial data for verekitug, demonstrating significant improvements in asthma symptom control and an 83% reduction in the need for rescue systemic steroids or CRSwNP surgery for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma. The drug also showed rapid and sustained reductions in type 2 inflammatory biomarkers. The company plans to begin Phase 3 trials in CRSwNP and severe asthma in Q1 2027.
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial
Upstream Bio presented new data from its Phase 2 VIBRANT trial for verekitug, demonstrating significant improvements in asthma symptom control for participants with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma. The data also showed reduced nasal polyp burden, sinonasal symptoms, and the need for steroids or surgery, alongside sustained reductions in type 2 inflammatory biomarkers. These findings support verekitug's potential as a best-in-class treatment with convenient quarterly dosing, with Phase 3 trials for CRSwNP and severe asthma planned for Q1 2027.
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
Upstream Bio (Nasdaq: UPB) reported its Q1 2026 financial results and provided updates on its clinical programs. The company is rapidly advancing Phase 3 programs for verekitug in severe asthma and CRSwNP, anticipating FDA meetings in mid-2026 and Phase 3 initiations in Q1 2027. Upstream Bio also announced a cap on further enrollment in its Phase 2 VENTURE trial for COPD, with data now expected in H2 2027, as it plans for a high-dose quarterly regimen Phase 3 trial.
Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM) and Upstream Bio, Inc. (UPB)
Two analysts have issued bullish sentiments on healthcare companies Icecure Medical (ICCM) and Upstream Bio, Inc. (UPB). Scott Henry from Alliance Global Partners maintained a Buy rating on Icecure Medical with a $1.00 price target, while Kate Dellorusso from LifeSci Capital maintained a Buy rating on Upstream Bio, Inc. with a $42.00 price target. The consensus for Icecure Medical is a "Moderate Buy" with a $2.00 target, and for Upstream Bio, Inc., it's a "Strong Buy" with a $43.75 target, indicating significant upside potential.
UPB Maintains Rating by Mizuho -- Price Target Lowered to $50.00
Mizuho analyst Joseph Catanzaro has maintained an "Outperform" rating for Upstream Bio (UPB) but lowered its price target to $50.00 from $51.00. This adjustment reflects a cautious outlook despite the positive rating, possibly due to concerns over near-term performance or market conditions. Upstream Bio, a biotechnology company focused on inflammatory diseases, currently has a low GF Score™ of 22 and significant insider selling, suggesting investors should proceed with caution despite the stock potentially being undervalued compared to the new price target.
Upstream Bio : Corporate Presentation May 2026 (May 13, 2026)
Upstream Bio released its corporate presentation for May 2026, outlining its focus on developing verekitug, a clinical-stage antagonist of the TSLP receptor, for severe respiratory diseases. The company plans to engage with the FDA in mid-2026 and initiate Phase 3 trials in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in Q1 2027, with data for its COPD trial expected in H2 2027. Upstream Bio emphasizes verekitug's potential for best-in-class efficacy with quarterly at-home dosing, supported by strong Phase 2 data in severe asthma and CRSwNP.
Press Release: Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
Upstream Bio reported its first quarter 2026 financial results and highlighted recent business achievements. The company is focused on developing therapeutics for inflammatory and immune-mediated diseases. Key updates on clinical trials and pipeline progress are expected to be included in the full report.
Upstream Bio, Inc. 1Q 2026: Revenue $1.03M, EPS $(0.75) — 10-Q Summary
Upstream Bio, Inc. reported its first-quarter 2026 financial results, which included revenue of $1.03 million and a diluted EPS of $(0.75). The company's net loss increased to $(40.59) million due to higher R&D and development costs as it advanced its clinical programs. Key highlights also included progress in its clinical trials for verekitug, pipeline expansion with a new COPD trial, and strategic collaborations.
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
Upstream Bio reported its first-quarter 2026 financial results, highlighting ongoing clinical development of verekitug for severe asthma, CRSwNP, and COPD. The company plans to initiate Phase 3 trials for severe asthma and CRSwNP in Q1 2027 and will cap enrollment in its Phase 2 COPD trial, with data expected in H2 2027. Upstream Bio also detailed its financial position, with $294.6 million in cash and investments, expected to fund operations through 2027.
Upstream Bio reports Q1 2026 net loss $40.6M; cash and short-term investments $294.6M
Upstream Bio reported a Q1 2026 net loss of $40.6 million, an increase from $27.3 million in Q1 2025, with cash and short-term investments totaling $294.6 million. The company is advancing its lead product, verekitug, with plans for End-of-Phase 2 FDA meetings in mid-2026 and Phase 3 initiations for severe asthma and CRSwNP in Q1 2027. Research and development expenses rose due to clinical and manufacturing activities for verekitug, while general and administrative expenses also increased.
TradingKey
This page provides an overview of Upstream Bio Inc (UPB) stock on the TradingKey platform, showing its current price, market cap, and links to financial data, discussions, and analysis. It also includes general disclaimers about investment risks and the nature of the information provided by TradingKey. The content suggests that TradingKey offers tools and resources for smarter investment decisions but advises users that it does not provide financial advice.
